TY - JOUR
T1 - Potential of combination of bone marrow nucleated and mesenchymal stem cells in complete spinal cord injury
AU - Katoh, Shojiro
AU - Dedeepiya, Vidyasagar D.
AU - Kuroda, Satoshi
AU - Iwasaki, Masaru
AU - Senthilku-Mar, Rajappa
AU - Preethy, Senthilkumar
AU - Abraham, Samuel J.K.
N1 - Publisher Copyright:
© 2021 Bentham Science Publishers.
PY - 2021
Y1 - 2021
N2 - Background: Cell-based therapies represent one of the definitive treatment approaches to SCI which, to become a routine clinical application, is marred by several known unknowns. The Bone Marrow Mononuclear Cells (BMMNCs) and Mesenchymal Stem Cells (MSCs) represent the most clinically applied cell types for SCI in humans, with safety established, and to an extent, efficacy reported. Methods: In this review, we have analysed the clinical studies performed using BMMNC and MSC for complete SCI separately, and the potential for applying those cells in combination. We have also analysed those factors whose outcome in animal studies of SCI could be evaluated in depth but the clinical outcome cannot be evaluated intrinsically owing to practical difficulties. Conclusion: A combination of these two cell types, BMMNC and MSC, has been proven to be ad-vantageous than applying them separately. Therefore, a thorough evaluation including the rationale and potential implications of applying these two therapies has been presented here, and we hypothe-size that such a combination is likely to improvise the outcome of a wholesome approach to spinal cord regeneration after SCI.
AB - Background: Cell-based therapies represent one of the definitive treatment approaches to SCI which, to become a routine clinical application, is marred by several known unknowns. The Bone Marrow Mononuclear Cells (BMMNCs) and Mesenchymal Stem Cells (MSCs) represent the most clinically applied cell types for SCI in humans, with safety established, and to an extent, efficacy reported. Methods: In this review, we have analysed the clinical studies performed using BMMNC and MSC for complete SCI separately, and the potential for applying those cells in combination. We have also analysed those factors whose outcome in animal studies of SCI could be evaluated in depth but the clinical outcome cannot be evaluated intrinsically owing to practical difficulties. Conclusion: A combination of these two cell types, BMMNC and MSC, has been proven to be ad-vantageous than applying them separately. Therefore, a thorough evaluation including the rationale and potential implications of applying these two therapies has been presented here, and we hypothe-size that such a combination is likely to improvise the outcome of a wholesome approach to spinal cord regeneration after SCI.
KW - Animal studies
KW - Bone Marrow Mononuclear Cells (BMMNC)
KW - Mesenchymal Stem Cells (MSC)
KW - Non-cell based regenerative therapies
KW - Spinal Cord Injury (SCI)
KW - Spinal cord regeneration
UR - http://www.scopus.com/inward/record.url?scp=85108303901&partnerID=8YFLogxK
U2 - 10.2174/1574888X15666201029160542
DO - 10.2174/1574888X15666201029160542
M3 - 簡易調査
C2 - 33121414
AN - SCOPUS:85108303901
SN - 1574-888X
VL - 16
SP - 385
EP - 399
JO - Current Stem Cell Research and Therapy
JF - Current Stem Cell Research and Therapy
IS - 4
ER -